by Peter Ciszewski | Jun 29, 2018
Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals provides and update on his company’s clinical trial programs. Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is...
by Peter Ciszewski | Jun 27, 2018
Luca Santarelli, MD of Therachon discusses achondroplasia, an autosomal dominant disorder characterized by dwarfism and disproportionate shortness of limbs, accompanied by life-altering complications. Achondroplasia is caused by a gene alteration (mutation) in...
by Peter Ciszewski | Jun 26, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. John Schall is Chief Executive Officer of Caregiver Action Network (CAN) and in this video he discusses the mission of the CAN and the many valuable resources his...
by Peter Ciszewski | Jun 23, 2018
Daniel de Boer, Founder and CEO of ProQR, discusses his company’s focus on Leber congenital amaurosis. This rare eye disorder primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. People with...
by Peter Ciszewski | Jun 21, 2018
Heather A. Lau, MD, Director, Lysosomal Storage Disease Program at NYU Langone in New York City discusses Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. This condition affects many different parts of the body and occurs almost...
